Recent research published in the New England Journal of Medicine indicates that semaglutide, a key ingredient in Wegovy, may effectively treat metabolic dysfunction-associated steatohepatitis (MASH), a liver disease affecting approximately 15 million Americans. A Phase 3 trial with 800 participants revealed that 63% of those receiving semaglutide injections experienced improvements in liver fat and inflammation compared to 34% in the placebo group. This condition is tied to obesity and Type 2 diabetes, making effective treatment crucial to prevent potential liver failure or the need for transplants.
After 72 weeks, nearly 63 percent of those who received semaglutide injections and around 34 percent of those on placebo shots saw their liver condition improve.
Patients may need a liver transplant, or can die from severe forms of metabolic dysfunction-associated steatohepatitis, highlighting the urgency of effective treatments.
#semaglutide #wegovy #metabolic-dysfunction-associated-steatohepatitis #liver-disease #clinical-trials
Collection
[
|
...
]